Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apixaban Impresses At ESC, Leading To Speculation About An Early Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol and Pfizer put an early end to the Phase III study successfully comparing their anticoagulant to aspirin, and the preliminary data bode well for further results due out mid-2011, but will they wait?

You may also be interested in...



Doubts Linger Over Whether AVERROES Gives Any Advantage To Apixaban

Bristol-Myers Squibb Co./Pfizer Inc. have evidence in hand that their investigational anticoagulant apixaban is useful in patients who can’t take warfarin. But any marketing gains for apixaban in this niche could be limited by physician skepticism about the patient population, assumptions that other similar drugs will be just as good in that population, and the recent FDA approval of the rival oral drug Pradaxa.

Doubts Linger Over Whether AVERROES Gives Any Advantage To Apixaban

Bristol-Myers Squibb Co./Pfizer Inc. have evidence in hand that their investigational anticoagulant apixaban is useful in patients who can’t take warfarin. But any marketing gains for apixaban in this niche could be limited by physician skepticism about the patient population, assumptions that other similar drugs will be just as good in that population, and the recent FDA approval of the rival oral drug Pradaxa.

Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors

As pivotal data on the new generation of anticoagulants continue to become public, differences in trial design and population are confusing attempts to predict competitive positioning for the new agents.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel